Your browser doesn't support javascript.
loading
Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer.
Wei, Shuo; Kozono, Shingo; Kats, Lev; Nechama, Morris; Li, Wenzong; Guarnerio, Jlenia; Luo, Manli; You, Mi-Hyeon; Yao, Yandan; Kondo, Asami; Hu, Hai; Bozkurt, Gunes; Moerke, Nathan J; Cao, Shugeng; Reschke, Markus; Chen, Chun-Hau; Rego, Eduardo M; Lo-Coco, Francesco; Cantley, Lewis C; Lee, Tae Ho; Wu, Hao; Zhang, Yan; Pandolfi, Pier Paolo; Zhou, Xiao Zhen; Lu, Kun Ping.
Afiliação
  • Wei S; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deac
  • Kozono S; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deac
  • Kats L; 1] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [2] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Pathology, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.
  • Nechama M; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deac
  • Li W; Department of Molecular Biosciences, University of Texas, Austin, Texas, USA.
  • Guarnerio J; 1] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [2] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Pathology, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.
  • Luo M; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deac
  • You MH; Division of Gerontology, Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.
  • Yao Y; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deac
  • Kondo A; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deac
  • Hu H; 1] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [2] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Bozkurt G; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
  • Moerke NJ; Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA.
  • Cao S; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
  • Reschke M; 1] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [2] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Pathology, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.
  • Chen CH; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deac
  • Rego EM; Department of Internal Medicine, University of São Paulo, Ribeirão Preto, Brazil.
  • Lo-Coco F; Department of Biomedicine and Prevention, Tor Vergata University and Santa Lucia Foundation, Rome, Italy.
  • Cantley LC; 1] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [2] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA.
  • Lee TH; Division of Gerontology, Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.
  • Wu H; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
  • Zhang Y; Department of Molecular Biosciences, University of Texas, Austin, Texas, USA.
  • Pandolfi PP; 1] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [2] Cancer Research Institute, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Pathology, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.
  • Zhou XZ; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deac
  • Lu KP; 1] Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Medicine, BIDMC, Harvard Medical School, Boston, Massachusetts, USA.. [3] Cancer Research Institute, Beth Israel Deac
Nat Med ; 21(5): 457-66, 2015 May.
Article em En | MEDLINE | ID: mdl-25849135
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tretinoína / Neoplasias da Mama / Leucemia Promielocítica Aguda / Regulação Leucêmica da Expressão Gênica / Regulação Neoplásica da Expressão Gênica / Peptidilprolil Isomerase Limite: Animals / Female / Humans Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tretinoína / Neoplasias da Mama / Leucemia Promielocítica Aguda / Regulação Leucêmica da Expressão Gênica / Regulação Neoplásica da Expressão Gênica / Peptidilprolil Isomerase Limite: Animals / Female / Humans Idioma: En Revista: Nat Med Assunto da revista: BIOLOGIA MOLECULAR / MEDICINA Ano de publicação: 2015 Tipo de documento: Article